of adults taking semaglutide 2.4 mg in three clinical trials reported nausea, against 16.1% on placebo, most often during or shortly after a dose increase.
Wharton et al., Diabetes, Obesity and Metabolism, 2022: STEP 1–3 pooled, semaglutide n = 2,117, placebo n = 1,262. Education about the medication, not a statement about any product.
Why we exist
The hard week is the dose increase.
People on GLP‑1 medications often meet stomach side effects around a dose increase. Dr. Carroll, a physician in Maitland, Florida, saw it in his own practice.
GLPrelief is what he formulated: physician-formulated daily support for people using GLP‑1 medications. Electrolytes, six B vitamins, four botanicals and fiber in one stick.









